Company profile
BioLineRx Ltd.
NASDAQ:BLRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MOTIXAFORTIDE | phase3 | — | 6 | active |
| MONARSEN | phase2 | — | 1 | no active trials |
| PERPHENAZINE 4-AMINOBUTYRATE | phase2 | — | 3 | no active trials |
| BL-1021 | phase1 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02073019 | phase1 | completed | 2014-08-01 | 2015-07-01 | BioLineRx, Ltd. | A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers |
| NCT03246529 | phase3 | active_not_recruiting | 2018-03-23 | 2020-12-22 | BioLineRx, Ltd. | A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) |
| NCT00480246 | phase1 | completed | 2007-05-01 | — | BioLineRx, Ltd. | A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer |
| NCT00567710 | phase2 | completed | 2008-07-01 | 2009-07-01 | BioLineRx, Ltd. | A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study |
| NCT01121380 | phase1 | terminated | 2011-06-01 | 2011-10-01 | BioLineRx, Ltd. | A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021 |
FDA applications (0)
No records yet.